Form 4: MaxCyte Director John Johnston Executes Stock Option and Sells Shares Under 10b5-1 Plan

Director John Johnston exercised stock options and sold shares of MaxCyte, Inc. under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On February 26, 2024, John Johnston, a director of MaxCyte, Inc., exercised stock options to acquire 5,000 shares of common stock at a price of $2.142 per share.
• Simultaneously, Johnston sold 5,000 shares of MaxCyte common stock at a weighted average price of $4.601, with individual sales prices ranging from $4.51 to $4.625.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on March 28, 2023.
• Following these transactions, Johnston directly owns 120,583 shares of MaxCyte common stock and holds options for 5,617 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports routine insider trading activity under a pre-arranged plan. It doesn't inherently indicate positive or negative prospects for the company.

Industry Context

This filing is a routine disclosure of insider transactions. Rule 10b5-1 plans are commonly used by corporate insiders to sell shares over time, avoiding accusations of trading on non-public information.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the effect is likely minimal given the relatively small number of shares involved.

Key Dates